Insider · CIK 0001569735
Lourdes Felix
Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.), BICX (BioCorRx Inc.), CHGA (Change Agents Corporation.), LRHC (La Rosa Holdings Corp.). First filing -, latest -.
In brief
Lourdes Felix files SEC Form 4 as CEO, CFO and director at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.), and also at BICX (BioCorRx Inc.), CHGA (Change Agents Corporation.), LRHC (La Rosa Holdings Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lourdes Felix has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | CHGA Change Agents Corporation. | AGrant or award Options (right to buy)derivative | +100,000 | $0.00 | $0 | 101,586 | Jul 13, 2026 |
| Jul 1, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 55,000 | Jul 2, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Dec 24, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 29, 2025 |
| Aug 11, 2025 | LRHC La Rosa Holdings Corp. | AGrant or award Common Stock | +600 | $0.00 | $0 | 600 | Aug 18, 2025 |
| Apr 24, 2024 | BICX BioCorRx Inc. | AGrant or award Common Stock, par value $0.001 | +224,196 | $0.00 | $0 | 314,795 | Jan 31, 2025 |
| Jul 2, 2024 | BICX BioCorRx Inc. | AGrant or award Common Stock, par value $0.001 | +500,000 | $0.00 | $0 | 814,795 | Jan 31, 2025 |
| Sep 30, 2024 | BICX BioCorRx Inc. | AGrant or award Common Stock, par value $0.001 | +15,625 | $0.00 | $0 | 830,420 | Jan 31, 2025 |
| Dec 31, 2024 | BICX BioCorRx Inc. | AGrant or award Common Stock, par value $0.001 | +13,158 | $0.00 | $0 | 843,578 | Jan 31, 2025 |
Questions about Lourdes Felix
Answered from the filings on this page, as of the latest one.
Is Lourdes Felix buying or selling?
Lourdes Felix has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lourdes Felix's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lourdes Felix has 0.
Where does Lourdes Felix file Form 4?
Lourdes Felix has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.); BICX (BioCorRx Inc.) as CEO and CFO; CHGA (Change Agents Corporation.); LRHC (La Rosa Holdings Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.